Patient Education & FAQ

Twenty Questions Families Ask About Alzheimer's Disease and Care in China

Families encounter many different kinds of Alzheimer's information: diagnostic blood tests, antibody medicines, surgical claims, research announcements, and overseas treatment offers. They do not all answer the same clinical question. A useful discussion separates evidence about diagnosis from evidence about symptoms, disease progression, safety, and everyday care. These answers reflect sources verifiable through September 2026 and are intended to help families prepare for a clinical consultation.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

  • No. Sleep problems, depression, medicines, sensory difficulties, metabolic disorders, and other neurological conditions can affect memory or thinking. Assessment considers the pattern over time, objective cognitive findings, everyday abilities, examination, and relevant investigations. Concrete examples of tasks that have become difficult are more informative than a general description of forgetfulness. A sudden change over hours or days needs timely evaluation for an acute cause, rather than being treated as ordinary aging or placed on the timetable of a routine chronic memory assessment.
  • The September 3, 2026 announcement concerned Chinese approval of a subcutaneous formulation for initiation. Approval does not establish immediate supply at a chosen hospital, an available appointment, or eligibility for a particular person. A different administration route does not remove diagnostic confirmation, MRI assessment, or discussion of risks. The family must verify the actual local approved instructions, training arrangements, administration support, and response to adverse events. US product instructions should not be copied as the treatment plan for every patient in China, and an unverified purchase is not a substitute for clinician-supervised initiation.
  • The family should know which clinician will prescribe, where necessary tests will occur, who will review results before another dose, and where to seek help at night. General cognitive assessment, review after a medicine change, and antibody surveillance may require different schedules. Eating, falls, wandering, and caregiver exhaustion also need attention as circumstances change. If a critical service is still unconfirmed, discuss it before leaving China. Waiting until treatment is interrupted or a new symptom develops makes coordination harder. A useful plan connects specialist recommendations to named local services and the support available in ordinary daily life.

Quick answer

Families encounter many different kinds of Alzheimer's information: diagnostic blood tests, antibody medicines, surgical claims, research announcements, and overseas treatment offers. They do not all answer the same clinical question. A useful discussion separates evidence about diagnosis from evidence about symptoms, disease progression, safety, and everyday care. These answers reflect sources verifiable through September 2026 and are intended to help families prepare for a clinical consultation.

Full guide

Families encounter many different kinds of Alzheimer's information: diagnostic blood tests, antibody medicines, surgical claims, research announcements, and overseas treatment offers. They do not all answer the same clinical question. A useful discussion separates evidence about diagnosis from evidence about symptoms, disease progression, safety, and everyday care. These answers reflect sources verifiable through September 2026 and are intended to help families prepare for a clinical consultation.

1. Does forgetfulness in an older adult mean Alzheimer's disease?

No. Sleep problems, depression, medicines, sensory difficulties, metabolic disorders, and other neurological conditions can affect memory or thinking. Assessment considers the pattern over time, objective cognitive findings, everyday abilities, examination, and relevant investigations. Concrete examples of tasks that have become difficult are more informative than a general description of forgetfulness. A sudden change over hours or days needs timely evaluation for an acute cause, rather than being treated as ordinary aging or placed on the timetable of a routine chronic memory assessment.

2. Is a positive Alzheimer's blood test enough to settle the diagnosis?

The result needs interpretation alongside symptoms and the specific assay's validated use. Some tests are intended for triage, while sufficiently accurate tests may support more definitive decisions in defined settings. Intermediate results, reference information, and the analytical platform matter. The 2025 Alzheimer's Association blood biomarker guideline makes conditional recommendations for specialist evaluation of people with objective cognitive impairment; it does not validate universal screening of asymptomatic people or every commercial product. Whether PET or cerebrospinal fluid investigation is needed depends on what remains uncertain and what decision the team is considering.

3. How does mild cognitive impairment differ from mild dementia?

Both can involve objectively measurable cognitive decline, but the effect on independent everyday functioning differs. Mild cognitive impairment can cause real difficulties and is not always due to Alzheimer's disease. Assessment must consider previous responsibilities and the contribution of physical, language, hearing, or visual limitations. In an anti-amyloid treatment indication, early disease refers to the relevant clinical stage of Alzheimer's-related impairment, not merely a memory problem noticed recently. A family should ask how the clinician determined both the likely cause and the functional stage rather than relying on one test score.

4. If a relative has Alzheimer's, will I inherit it?

A relative's diagnosis does not establish that another family member will develop the disease. APOE risk information differs from a finding of a pathogenic variant associated with an inherited form, and APOE alone is not diagnostic. Unusually young onset or a strong pattern across generations may justify specialist discussion of genetic counseling and appropriate testing. Counseling should address what a result could establish, what it could not predict, and its implications for relatives. A consumer genetics report should not be interpreted as a timetable for future disease, and testing should have a clearly explained clinical purpose.

5. Can current medicines cure or reverse Alzheimer's disease?

Approved treatments should not be described as cures. Symptomatic medicines may help some aspects of cognition or daily function, while anti-amyloid antibodies have shown average slowing of decline in eligible early-stage study populations. Reducing amyloid, changing the rate of deterioration on a scale, and restoring lost independence are different outcomes. A relative slowing reported in a trial is not the percentage by which an individual will improve and cannot automatically be converted into additional years of life. Treatment discussions should include function, adverse effects, monitoring, and the burden placed on the household.

6. Should donepezil or memantine be stopped if decline continues?

Continued deterioration does not by itself determine whether a medicine should be stopped. The clinician should review the diagnosis, stage, actual adherence, tolerability, and other influences on function. Disease severity alone is not a reason to automatically discontinue an acetylcholinesterase inhibitor. If a cognitive enhancer is withdrawn, a planned reduction with observation may help identify whether a meaningful deterioration is related to the change. Report problems such as weight loss, nausea, or fainting. Restarting after a substantial interruption requires medicine-specific advice rather than assuming that the previous dose remains appropriate.

7. Who may be assessed for lecanemab or donanemab?

Assessment generally concerns people at the appropriate early clinical stage of Alzheimer's disease, with suitable evidence of amyloid pathology and an acceptable safety evaluation. MRI findings, accompanying conditions, anticoagulant use, and the ability to sustain follow-up all matter. APOE information may inform discussion of ARIA risk but does not replace the rest of the evaluation. Being able to pay, being willing to travel to China, or having one positive blood result does not independently establish eligibility. Actual treatment must follow the applicable local approved information and the responsible clinical team's assessment.

8. Which antibody works better?

Comparing headline percentages from separate trials does not establish a winner. CLARITY AD and TRAILBLAZER-ALZ 2 differed in their populations, outcome measures, follow-up periods, and analyses. Without an appropriate direct comparison, those differences cannot be removed simply by placing two numbers side by side. The clinical choice also involves the administration schedule, safety profile, monitoring requirements, and whether the proposed arrangement is sustainable. Ask the physician why a particular option fits the person's circumstances. A recommendation should explain the relevant evidence and uncertainty rather than repeat the largest advertised percentage.

9. What is ARIA, and can MRI be skipped when there are no symptoms?

Amyloid-related imaging abnormalities include edema and hemorrhagic changes that can occur during anti-amyloid treatment. Some are asymptomatic, which is one reason scheduled MRI remains important. Others may involve headache, visual or awareness changes, or walking difficulty. Sudden weakness, speech disturbance, or seizures need immediate medical evaluation with the antibody history made available. The household should not diagnose ARIA versus stroke independently. CT does not replace the required MRI surveillance, and a scan needs clinical review before decisions about subsequent treatment. Feeling well is useful information, but it does not establish that an examination can be omitted.

10. Can antibody treatment finish after a fixed number of doses?

The strategy depends on the product and the clinical circumstances. Donanemab prescribing information allows consideration of discontinuation when amyloid reaches minimal levels on PET, but this is not a guarantee of permanent cure after a universal number of doses. Lecanemab also has stage-specific administration options, with limitations in the long-term clinical evidence for some maintenance transitions. Continuing, interrupting, or ending treatment requires consideration of the applicable label, imaging, symptoms, and personal burden. A favorable change in a blood result is not a standalone instruction to cancel further treatment or monitoring.

11. Does Chinese approval of subcutaneous lecanemab mean treatment can start at home?

The September 3, 2026 announcement concerned Chinese approval of a subcutaneous formulation for initiation. Approval does not establish immediate supply at a chosen hospital, an available appointment, or eligibility for a particular person. A different administration route does not remove diagnostic confirmation, MRI assessment, or discussion of risks. The family must verify the actual local approved instructions, training arrangements, administration support, and response to adverse events. US product instructions should not be copied as the treatment plan for every patient in China, and an unverified purchase is not a substitute for clinician-supervised initiation.

12. Can sodium oligomannate still be obtained and reimbursed as older advertisements suggest?

Its historical conditional approval does not establish present supply or reimbursement. A December 2025 regulatory disclosure described the expiry of registration and cessation of commercial production, with further regulatory requirements before restarting. This review did not identify reliable official confirmation that production had resumed. The medicine was also included in the 2025 national reimbursement catalogue removal list, whose transition ended in June 2026. Current status must be checked with regulators, legitimate hospitals, and the relevant payer. An older advertisement or reimbursement statement should not be treated as a September 2026 commitment to supply or payment.

13. Are there new medicines for agitation or aggression?

Assessment should first consider pain, delirium, constipation, environmental triggers, and difficulty understanding care. Non-drug approaches and any need for medication follow from that assessment. In April 2026, the FDA approved Auvelity for agitation associated with dementia due to Alzheimer's disease in adults; brexpiprazole also has an applicable US indication. Both have specific safety considerations and are not simply as-needed sedatives for a family to add independently. A US approval does not establish the same indication or availability in China. Any prescription needs review of accompanying medicines, individual risks, and ongoing benefit.

14. Can cervical lymphatic surgery or deep brain stimulation restore memory?

The evidence does not support presenting these procedures as established ways to restore memory in Alzheimer's disease. China's National Health Commission has prohibited cervical lymphatic anastomosis as routine clinical treatment for the condition. Deep brain stimulation research has not established a broadly applicable cognitive benefit, and exploratory subgroup findings do not create an individual surgical indication. A registry entry or ethics document should prompt questions about research design, current recruitment, alternatives, and risk. It does not demonstrate that a paid treatment package has already been shown to work or is permitted as ordinary clinical care.

15. What about 40-Hz stimulation, ultrasound, or low-dose radiation?

These areas require a distinction between feasibility, biological or imaging changes, and reliable clinical benefit. Some studies are small, some have not improved their principal cognitive outcomes, and some announcements concern protocols rather than results. Animal findings, changes in a few participants, or a regulatory development designation do not establish a mature treatment. Families should not construct flashing devices or reproduce experimental parameters at home; seizure history and other individual factors may affect safety. Participation in a legitimate study requires understanding its objective, the alternatives, and the practical demands of follow-up.

16. Does a phase 3 announcement mean I can enroll and receive effective treatment?

Entering phase 3, completing recruitment, reporting initial results, and receiving marketing approval are separate events. The 2026 phase 2 CELIA study of diranersen did not meet its primary dose-response endpoint, despite some encouraging findings; semaglutide's EVOKE program also did not demonstrate the expected clinical benefit. A selective news summary may omit those distinctions. Anyone considering a trial should check the current registry record, the status of the particular center, and individual eligibility. Randomization or placebo may be part of the study, and requesting participation guarantees neither enrollment nor receipt of an effective therapy.

17. What does a year of care in China cost, and does a commercial catalogue guarantee coverage?

There is no verified total that applies to every household. Investigation, medicine, administration, MRI, assessment of abnormal findings, accommodation, and companionship can all change the cost. Ask the hospital for an itemized estimate in RMB based on the actual proposed plan. Inclusion of relevant antibodies in China's commercial innovative medicine catalogue does not mean that the basic medical insurance fund pays for them or that every commercial policy covers them. Contract terms, prior authorization, exclusions, and out-of-pocket responsibility must be confirmed separately. A drug price alone does not describe the annual cost of care.

18. How should a family choose a Chinese hospital?

Match the service to the unresolved need. Diagnostic uncertainty may call for a memory clinic with neuropsychological and imaging support. Antibody care requires suitable screening, MRI review, and a response to ARIA. Severe behavioral symptoms may benefit from geriatric psychiatric input alongside other specialists. Official service descriptions and published institutional research can help identify relevant expertise, but neither guarantees an appointment, stock, or a personal outcome. Confirm international patient access, language assistance, cost arrangements, and follow-up before travel, and let the institution assess the available records before assuming it can provide the requested treatment.

19. What records are needed, and can the patient travel alone?

Prepare a chronology of symptoms and functional changes, complete investigation reports and images, the actual medication list, important adverse reactions, and clinical contacts. Previous antibody treatment also requires administration dates and sequential MRI records. Independent travel must be assessed against cognition, navigation, communication, and self-care, not just physical walking ability. A trusted companion may be particularly important where the person becomes lost or struggles with unfamiliar settings. Airline assistance does not automatically provide continuous personal care or medical escort. The proposed itinerary should fit the person's abilities and have a practical plan for disruption.

20. What makes the return-home follow-up plan workable?

The family should know which clinician will prescribe, where necessary tests will occur, who will review results before another dose, and where to seek help at night. General cognitive assessment, review after a medicine change, and antibody surveillance may require different schedules. Eating, falls, wandering, and caregiver exhaustion also need attention as circumstances change. If a critical service is still unconfirmed, discuss it before leaving China. Waiting until treatment is interrupted or a new symptom develops makes coordination harder. A useful plan connects specialist recommendations to named local services and the support available in ordinary daily life.

Sources

Related guides